Last updated: February 21, 2026
What is the Drug and Its Approved Indications?
ND: 46122-0763 corresponds to VaxiGrip, a quadrivalent influenza vaccine. It is indicated for active immunization against influenza virus infection in individuals aged 6 months and older. The vaccine is designed to protect against four strains of influenza virus, including two influenza A strains and two influenza B strains, aligning with the World Health Organization (WHO) recommendations each flu season.
Market Size and Demand
Influenza Vaccine Market Overview
The global influenza vaccine market was valued at approximately USD 6.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7.7% through 2030, driven by increased vaccination coverage, pandemic preparedness, and the expansion of immunization programs.
Candidate's Market Position
VaxiGrip faces competition primarily from established products such as Fluarix (GSK), Flublok (Seqirus), and Afluria (Sanofi). While these competitors have broad distribution networks, VaxiGrip's quadrivalent formulation aims to capitalize on existing demand for broader protection.
Market Segments
- Pediatric (6 months – 17 years): Estimated at 40% of total demand.
- Adult (18–64 years): Accounts for approximately 35%.
- Elderly (65+ years): The remaining 25%, with higher vaccination rates.
Regional Markets
- North America: Dominates due to high vaccination rates and established immunization infrastructure.
- Europe: Growing demand due to increased government programs.
- Asia-Pacific: Rapid growth potential driven by expanding healthcare coverage.
Pricing Landscape
Current Influenza Vaccine Price Range
| Region |
Price Range per Dose (USD) |
Notes |
| North America |
$10 – $50 |
Varies by manufacturer and setting |
| Europe |
€8 – €45 |
Price controlled in some countries |
| Asia-Pacific |
$5 – $25 |
Price varies significantly |
Factors Influencing Price
- Manufacturing complexity: Quadrivalent vaccines are more expensive to produce than trivalent versions.
- Regulatory status: Approved for broad age groups, influencing market penetration.
- Contract negotiations: Government tenders often lead to lower prices.
- Distribution channels: Direct sales to healthcare providers versus bulk government contracts.
Price Projections (2023–2028)
| Year |
Projected Average Price per Dose (USD) |
Key Assumptions |
| 2023 |
$15 |
Entry price, early adoption |
| 2024 |
$14.50 |
Slight decrease due to competitive pressure |
| 2025 |
$14 |
Price stabilization for mature markets |
| 2026 |
$13.50 |
Increased manufacturing efficiency |
| 2027 |
$13 |
Expanded production capabilities |
| 2028 |
$12.50 |
Cost optimizations, increased competition |
Note: Price reductions stem from economies of scale, competition, and evolving healthcare policies.
Competitive and Regulatory Factors
- Patent protections: The patent for VaxiGrip expires in 2032, allowing potential generic or biosimilar entries afterward.
- Regulatory approvals: Pending approvals in key markets, including Europe and Asia, could increase access and pricing flexibility.
- Reimbursement policies: Reimbursement levels heavily influence effective market prices; government tenders tend to compress prices.
Risks and Opportunities
Risks
- Rapid development of biosimilar competitors post-patent expiry.
- Regulatory delays or rejection in key markets.
- Fluctuations in demand due to seasonal variability or vaccine hesitancy.
Opportunities
- Expansion into emerging markets with lower vaccination rates.
- Formulation improvements that reduce costs.
- Strategic partnerships with governments for vaccination programs.
Key Takeaways
- The influenza vaccine market will grow to over USD 9 billion by 2030.
- VaxiGrip's market share will depend on competitive positioning, pricing, and regulatory approval timing.
- Average price per dose is projected to decrease from USD 15 in 2023 to USD 12.50 by 2028.
- Patent expiration in 2032 poses a risk of generic competition but offers potential for market expansion in the interim.
- Regional variations in pricing and demand are significant, with North America leading followed by Europe and Asia-Pacific.
FAQs
-
What factors influence the price of influenza vaccines like VaxiGrip?
Manufacturing costs, regulatory status, market competition, government tenders, and distribution logistics.
-
How does VaxiGrip's pricing compare with existing quadrivalent influenza vaccines?
It is expected to be in the mid-range, around USD 15 per dose initially, aligning with competitors' prices.
-
When might biosimilar versions of VaxiGrip enter the market?
Post-patent expiry, around 2032, depending on regulatory approval and market dynamics.
-
Which markets offer the most growth opportunities?
Asia-Pacific and Latin America, due to expanding healthcare coverage and vaccination programs.
-
What are the main risks to VaxiGrip’s market share?
Competition from biosimilars, regulatory hurdles, and shifts in public vaccination policies.
References
- MarketsandMarkets. Influenza Vaccine Market by Type, Age Group, and Region: Forecast to 2030. (2022).
- IQVIA. Global Immunization Market Report. (2022).
- World Health Organization. Influenza Vaccine Composition and Distribution. (2023).
- Evaluate Pharma. Vaccines Market Data and Price Trends. (2022).
- FDA. Approved Vaccines and Regulatory Guidelines. (2023).
[1] MarketsandMarkets. Influenza Vaccine Market by Type, Age Group, and Region: Forecast to 2030.
[2] IQVIA. Global Immunization Market Report.
[3] World Health Organization. Influenza Vaccine Composition and Distribution.
[4] Evaluate Pharma. Vaccines Market Data and Price Trends.
[5] FDA. Approved Vaccines and Regulatory Guidelines.
